CN111202842A - Pharmaceutical composition for treating hyaluronic acid vascular embolism - Google Patents
Pharmaceutical composition for treating hyaluronic acid vascular embolism Download PDFInfo
- Publication number
- CN111202842A CN111202842A CN202010084854.8A CN202010084854A CN111202842A CN 111202842 A CN111202842 A CN 111202842A CN 202010084854 A CN202010084854 A CN 202010084854A CN 111202842 A CN111202842 A CN 111202842A
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- pharmaceutical composition
- vascular embolism
- treating
- embolism
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002674 hyaluronan Polymers 0.000 title claims abstract description 44
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title claims abstract description 43
- 229960003160 hyaluronic acid Drugs 0.000 title claims abstract description 43
- 208000005189 Embolism Diseases 0.000 title claims abstract description 40
- 230000002792 vascular Effects 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 27
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 25
- 102000001974 Hyaluronidases Human genes 0.000 claims abstract description 25
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 25
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 23
- 238000002347 injection Methods 0.000 claims abstract description 22
- 239000007924 injection Substances 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims description 15
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims 1
- 229940099552 hyaluronan Drugs 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 abstract description 12
- 210000004204 blood vessel Anatomy 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000017074 necrotic cell death Effects 0.000 abstract description 4
- 206010047513 Vision blurred Diseases 0.000 abstract description 3
- 210000000056 organ Anatomy 0.000 abstract description 3
- 230000002537 thrombolytic effect Effects 0.000 abstract description 3
- 208000034656 Contusions Diseases 0.000 abstract description 2
- 208000034526 bruise Diseases 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 206010008088 Cerebral artery embolism Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000010849 intracranial embolism Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102400001284 Vessel dilator Human genes 0.000 description 2
- 108010090012 atrial natriuretic factor prohormone (31-67) Proteins 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating hyaluronic acid vascular embolism, which relates to the technical field of medical cosmetology, and comprises the following raw materials: 1000 portions of hyaluronidase and 3000u, 5 to 15mg of aspirin. The pharmaceutical composition for treating the hyaluronic acid vascular embolism disclosed by the invention can immediately play a role in thrombolysis by utilizing a compound preparation of hyaluronidase and small-dose aspirin which enters a human body through intravenous injection, various serious complications and tissue and organ necrosis caused by the fact that hyaluronic acid is mistakenly injected into blood vessels are solved, the pharmaceutical composition can be used for treating the hyaluronic acid vascular embolism within 30 minutes, the effect is achieved within 5 minutes after injection, the symptoms of mottle, bruise, blurred vision and the like of local tissues of the embolism are relieved by 90% -100%, only one treatment is needed, and the blank is filled for the effective treatment of salving hyaluronic acid injection to fill the complicated vascular embolism; the earlier the pharmaceutical composition of the present invention is applied, the better the effect.
Description
Technical Field
The invention relates to the technical field of medical cosmetology, in particular to a pharmaceutical composition for treating hyaluronic acid vascular embolism.
Background
Since the last 80 century, Hyaluronic Acid (HA) was used for soft tissue filling, and compared with autologous fat transplantation or botulinum toxin injection, Hyaluronic Acid HAs the advantages of small wound, quick recovery and instant effect, and is favored by many beauty-seeking people, so Hyaluronic Acid is also the most widely used skin filling preparation at present, and the number of people who receive Hyaluronic Acid injection filling is hundreds of thousands of times per year. However, with the wide application of hyaluronic acid, many complications often appear after hyaluronic acid injection filling, the hyaluronic acid injection filling is injected into a blood vessel by mistake, which causes lumen blockage, or a needle head punctures the blood vessel wall to start endogenous blood coagulation to form thrombus, but even though hyaluronic acid is not injected into the blood vessel or punctures the blood vessel wall, the hyaluronic acid injection filling has better tissue penetrability, can generate resonance with body fluid, blood and even water in cells of a human body to generate vascular embolism with different degrees, the vascular embolism is the most serious complication after hyaluronic acid injection filling, and is usually irreversible recovery, and serious patients can also have local tissue necrosis, blindness and even cerebral embolism to cause disability.
The treatment of the blood vessel embolism caused by the hyaluronic acid has no unified view, and the high-pressure oxygen cabin or the blood vessel dilator is adopted for rescue, but the former only improves the blood stasis in the embolism area, the blood stasis and scar are slowly faded, the recovery is slow, and the latter can obviously relieve the thromboembolism, but under the push of the blood vessel dilator, the embolism may flow into the carotid artery or the eye, and the risk of retinal embolism or cerebral embolism is accelerated.
Disclosure of Invention
Therefore, the invention provides a pharmaceutical composition for treating hyaluronic acid vascular embolism, which aims to solve the problems of slow recovery, risk of accelerating retinal embolism or cerebral embolism and the like in the existing method for treating hyaluronic acid vascular embolism.
In order to achieve the above purpose, the invention provides the following technical scheme:
according to a first aspect of the invention, a pharmaceutical composition for treating hyaluronic acid vascular embolism comprises the following raw materials: 1000 portions of hyaluronidase and 3000u, 5 to 15mg of aspirin.
The hyaluronidase in the pharmaceutical composition is an alkaline protein, can be safely applied to clinical tests, and has the functions of eliminating vascular embolism or blood vessel external compression and recovering tissue perfusion. The hyaluronidase is also a specific enzyme, only has activity on the hyaluronic acid, degrades the hyaluronic acid in vivo, temporarily reduces the viscosity of intercellular substance, improves the liquid permeability of tissues to facilitate absorption, meanwhile, the hyaluronidase can not pass through the blood brain barrier and can be quickly removed in plasma, the concentration of the hyaluronidase in the plasma can not be continuously increased by repeated injection, the hyaluronidase is prepared into nanoparticles in time, the half-life period of intravenous injection is only 3.5min, and the tissue distribution shows that the hyaluronidase is mainly absorbed by liver and hardly exists in urine and bile. The pharmaceutical composition of the present invention employs aspirin in order to inhibit intravascular coagulation clot formation. The pharmaceutical composition of the invention utilizes the compound preparation of hyaluronidase and small dose of aspirin to enter human body through intravenous injection to immediately play a role in thrombolysis, and solves various serious complications and tissue and organ necrosis caused by the mistaken entry of hyaluronic acid into blood vessels.
Further, the composition comprises the following raw materials: hyaluronidase 2000u, aspirin 10 mg.
Further, the aspirin is arginine aspirin for injection.
Further, the composition also comprises 40-60ml of physiological saline.
Further, the composition also includes 50ml of physiological saline.
The composition is added with physiological saline to play a role in dissolving the hyaluronidase and the aspirin, and the hyaluronidase and the aspirin can be dissolved more effectively by further limiting the addition amount of the physiological saline, so that the functions of the hyaluronidase and the aspirin in a human body are optimized.
Further, the composition is administered by intravenous injection.
The invention has the following advantages:
the pharmaceutical composition for treating the hyaluronic acid vascular embolism disclosed by the invention can immediately play a role in thrombolysis by utilizing a compound preparation of hyaluronidase and small-dose aspirin which enters a human body through intravenous injection, various serious complications and tissue and organ necrosis caused by the fact that hyaluronic acid is mistakenly injected into blood vessels are solved, the pharmaceutical composition can be used for treating the hyaluronic acid vascular embolism within 30 minutes, the effect is achieved within 5 minutes after injection, the symptoms of mottle, bruise, blurred vision and the like of local tissues of the embolism are relieved by 90% -100%, only one treatment is needed, and the blank is filled for the effective treatment of salving hyaluronic acid injection to fill the complicated vascular embolism; the earlier the pharmaceutical composition of the present invention is applied, the better the effect.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A pharmaceutical composition for treating hyaluronic acid vascular embolism, which comprises the following raw materials: 1000u of hyaluronidase, 5mg of arginine aspirin for injection and 40ml of normal saline.
The mode of administration of the composition is intravenous injection.
Example 2
A pharmaceutical composition for treating hyaluronic acid vascular embolism, which comprises the following raw materials: 3000u of hyaluronidase, 15mg of arginine aspirin for injection and 60ml of normal saline.
The mode of administration of the composition is intravenous injection.
Example 3
A pharmaceutical composition for treating hyaluronic acid vascular embolism, which comprises the following raw materials: 2000u of hyaluronidase, 10mg of arginine aspirin for injection and 50ml of normal saline.
The mode of administration of the composition is intravenous injection.
Example 4
A pharmaceutical composition for treating hyaluronic acid vascular embolism, which comprises the following raw materials: 1500u of hyaluronidase, 8mg of arginine aspirin for injection and 45ml of normal saline.
The mode of administration of the composition is intravenous injection.
Example 5
A pharmaceutical composition for treating hyaluronic acid vascular embolism, which comprises the following raw materials: 2500u hyaluronidase, 12mg arginine aspirin for injection, and 55ml physiological saline.
The mode of administration of the composition is intravenous injection.
The pharmaceutical composition for treating the hyaluronic acid vascular embolism disclosed by the invention can immediately play a role in dissolving the thrombus after entering a human body through intravenous injection by utilizing a compound preparation of hyaluronidase and small-dose aspirin, and can be used for relieving the hyaluronic acid vascular embolism within 30 minutes, the effect is taken 5 minutes after injection, and the symptoms of blue and green flower spots, blurred vision and the like of local tissues of embolism are relieved by 90-100%, and only one-time treatment is needed.
The medical composition of the embodiment 3 of the invention is applied to 18 customers in 2016-2019 by the department of hospital injection, and has obvious clinical effect, wherein the 18 customers have local facial spots, numbness or unclear vision and other vascular embolism symptoms after the facial injection of hyaluronic acid, medical staff immediately perform hyaluronidase allergic tests on the customers when the patients have the obvious vascular embolism symptoms, and immediately inject 50ml of physiological saline, 2000u of hyaluronidase and 10mg of arginine aspirin for injection into veins after the patients are determined to be negative, the symptoms are gradually relieved within 5 minutes after the intravenous injection, and the symptoms completely disappear from 20 minutes to 30 minutes, and no discomfort exists in the customers.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (6)
1. The pharmaceutical composition for treating hyaluronic acid vascular embolism is characterized by comprising the following raw materials: 1000 portions of hyaluronidase and 3000u, 5 to 15mg of aspirin.
2. The pharmaceutical composition for treating hyaluronic acid vascular embolism according to claim 1, wherein the composition comprises the following raw materials: hyaluronidase 2000u, aspirin 10 mg.
3. The pharmaceutical composition for treating hyaluronic acid vascular embolism according to claim 1, wherein the aspirin is arginine aspirin for injection.
4. The pharmaceutical composition for the treatment of hyaluronic acid vascular embolism according to claim 1, wherein the composition further comprises 40-60ml of physiological saline.
5. The pharmaceutical composition for the treatment of hyaluronic acid vascular embolism according to claim 4, wherein said composition further comprises 50ml of physiological saline.
6. The pharmaceutical composition for the treatment of hyaluronan vascular embolism according to claim 1, wherein the composition is administered intravenously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010084854.8A CN111202842A (en) | 2020-02-10 | 2020-02-10 | Pharmaceutical composition for treating hyaluronic acid vascular embolism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010084854.8A CN111202842A (en) | 2020-02-10 | 2020-02-10 | Pharmaceutical composition for treating hyaluronic acid vascular embolism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111202842A true CN111202842A (en) | 2020-05-29 |
Family
ID=70780950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010084854.8A Pending CN111202842A (en) | 2020-02-10 | 2020-02-10 | Pharmaceutical composition for treating hyaluronic acid vascular embolism |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111202842A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023049878A1 (en) * | 2021-09-25 | 2023-03-30 | Med Progress, LLC | Reducing or inhibiting tissue damage using hyaluronidase administration |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380329A (en) * | 2008-10-29 | 2009-03-11 | 海南本创医药科技有限公司 | Preparation method of arginine aspirin and powder and injection preparation thereof |
| CN104693029A (en) * | 2013-12-05 | 2015-06-10 | 蚌埠丰原涂山制药有限公司 | A preparing method of arginine aspirin sterile powder |
| CN105412918A (en) * | 2015-11-18 | 2016-03-23 | 上海交通大学医学院附属第九人民医院 | Drug formula capable of dissolving cross-linked hyaluronic acid thrombosis |
| CN105769882A (en) * | 2016-03-14 | 2016-07-20 | 北京赛德维康医药研究院 | Pharmaceutical composition for inhibiting thrombosis and application of pharmaceutical composition |
-
2020
- 2020-02-10 CN CN202010084854.8A patent/CN111202842A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101380329A (en) * | 2008-10-29 | 2009-03-11 | 海南本创医药科技有限公司 | Preparation method of arginine aspirin and powder and injection preparation thereof |
| CN104693029A (en) * | 2013-12-05 | 2015-06-10 | 蚌埠丰原涂山制药有限公司 | A preparing method of arginine aspirin sterile powder |
| CN105412918A (en) * | 2015-11-18 | 2016-03-23 | 上海交通大学医学院附属第九人民医院 | Drug formula capable of dissolving cross-linked hyaluronic acid thrombosis |
| CN105769882A (en) * | 2016-03-14 | 2016-07-20 | 北京赛德维康医药研究院 | Pharmaceutical composition for inhibiting thrombosis and application of pharmaceutical composition |
Non-Patent Citations (2)
| Title |
|---|
| OKHUAQIAOCHEN: "注射玻尿酸导致血管栓塞的临床表现及救治", 《HTTPS://LEMON.BAIDU.COM/A?ID=274008》 * |
| 医药工业: "注射用阿司匹林精氨酸", 《医药工业》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023049878A1 (en) * | 2021-09-25 | 2023-03-30 | Med Progress, LLC | Reducing or inhibiting tissue damage using hyaluronidase administration |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Winter et al. | Sclerotherapy for treatment of hemangiomas | |
| Kassir et al. | Extensive necrosis after injection of hyaluronic acid filler: case report and review of the literature | |
| Siniluoto et al. | Percutaneous sclerotherapy of venous malformations of the head and neck using sodium tetradecyl sulphate (sotradecol) | |
| HODGE III | Intraosseous infusions: a review | |
| US20190336445A1 (en) | Devices and methods for injectable vascular sclerofoams using a carrier matrix and uses thereof | |
| Komorowska-Timek et al. | Treatment of radial and ulnar artery pseudoaneurysms using percutaneous thrombin injection | |
| Chen et al. | Clinical neurorestorative therapeutic guideline for brainstem hemorrhage (2020 China version) | |
| Gleeson et al. | Acute fatal fat tissue embolism after autologous fat transfer in a patient with lupus profundus | |
| HU217961B (en) | Process for producing pharmaceutical composition containing lys-plasminogen for preventing and treating ischemic events and reperfusive injuries resulting therefrom | |
| Sugar et al. | Some complications of vertebral angiography | |
| Hung et al. | Unilateral vision loss after hyaluronic acid injection: a case report | |
| CN111202842A (en) | Pharmaceutical composition for treating hyaluronic acid vascular embolism | |
| Zhang et al. | Retrospective study of vascular complications caused by hyaluronic acid injection | |
| Hepler et al. | On the occurrence of blindness in association with blepharoplasty | |
| Hieshima et al. | Intravascular balloon embolization of a large mid-basilar artery aneurysm: Case report | |
| Asensio-Sánchez | Central retinal artery occlusion following facial injection of hyaluronic acid | |
| Yang et al. | Super‐selective intra‐arterial dissolution therapy for lingual artery occlusion resulting due to the use of hyaluronic acid for chin augmentation: The first reported case | |
| CN107648598B (en) | A kind of pharmaceutical composition for treating acute ischemic cerebral apoplexy | |
| Lu et al. | Restoration of autologous arteriovenous fistula by vascular stripping in a hemodialysis patient with venous neointimal hyperplasia | |
| Mahallati et al. | Therapeutic embolization of a pseudoaneurysm of the superior gluteal artery occurring as a complication of bone marrow biopsy: case report | |
| Sherry | Thrombolytic therapy for noncoronary diseases | |
| Alessio et al. | Ischemical problems after filler injections: Anatomical details and practical guide lines to avoid disasters | |
| CN115624522B (en) | Drug-loaded ethanol injection capable of preventing acute increase of pulmonary arterial pressure and preparation method and application thereof | |
| Pritzker et al. | Vascular Compromise | |
| CN104116853A (en) | Beautyberry leaf injection with astringency and hemostasis effects and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200529 |
|
| RJ01 | Rejection of invention patent application after publication |